Blood Group Typing Market by Test Type, Technology, Sample Type, Automation Level, Application, End User

List of Tables

The Blood Group Typing Market is projected to grow by USD 4.42 billion at a CAGR of 8.26% by 2032.

KEY MARKET STATISTICS
Base Year [2025]	USD 2.54 billion
Estimated Year [2026]	USD 2.74 billion
Forecast Year [2032]	USD 4.42 billion
CAGR (%)	8.26%

Blood group typing is a core pillar of transfusion medicine, transplant compatibility, prenatal care, and emergency response. The market spans ABO and Rh typing, extended antigen phenotyping, antibody screening, crossmatching, molecular blood group genotyping, reagents, gel cards, microplates, analyzers, and laboratory information connectivity.

Demand is supported by the scale of global blood collection and the clinical requirement to prevent hemolytic transfusion reactions. The World Health Organization reports approximately 118.5 million blood donations worldwide, with high-income countries collecting a disproportionate share relative to population. This uneven distribution is driving investment in safer, faster, and more standardized blood bank diagnostics across both mature and emerging healthcare systems.

Transformative Shifts in the Blood Group Typing Landscape

The blood group typing landscape is shifting from manual tube testing toward automated immunohematology platforms, gel column agglutination, solid-phase methods, and molecular assays. Hospitals and reference laboratories are prioritizing workflows that reduce subjective interpretation, improve traceability, and support high-throughput donor and patient testing.

Regulatory and clinical expectations are also becoming more rigorous. The European Union In Vitro Diagnostic Regulation, FDA oversight of transfusion-related diagnostics, and accreditation frameworks from organizations such as AABB reinforce the need for validated assays, quality controls, and documented performance. These shifts favor suppliers that can combine reliable reagents, automation, informatics, and service support.

Cumulative Impact of Artificial Intelligence in Blood Group Typing

Artificial intelligence is increasingly relevant to blood group typing through image recognition, automated reaction grading, anomaly detection, inventory optimization, and decision support. AI-enabled tools can help laboratories flag discrepant results, prioritize complex antibody investigations, and reduce variability in interpretation when paired with validated quality systems.

The cumulative impact is not replacement of laboratory professionals but augmentation of high-volume and high-risk workflows. AI can strengthen donor-recipient matching by integrating phenotype, genotype, antibody history, and inventory data. Adoption will depend on explainable algorithms, cybersecurity, auditability, regulatory validation, and seamless integration with blood bank information systems.

Key Regional Insights for Blood Group Typing

Asia-Pacific is becoming a major growth engine as China, India, Japan, South Korea, Australia, and ASEAN markets expand hospital capacity, blood bank modernization, and molecular diagnostics adoption. Large patient populations, rising surgical volumes, increasing chronic disease care, and national blood safety initiatives create sustained demand for ABO/Rh typing, antibody screening, crossmatching, and scalable automation.

North America remains highly advanced due to strong hospital networks, established blood collection systems, reference laboratories, patient blood management programs, and rigorous transfusion standards. Europe benefits from mature immunohematology infrastructure, hemovigilance systems, and IVDR-driven quality expectations. Latin America is improving access through public and private investment, with Brazil and Mexico supporting broader modernization of blood bank diagnostics. The Middle East is building premium hospital systems and centralized testing capacity, particularly across high-investment healthcare hubs. Africa presents the greatest unmet need, where WHO data showing lower donation rates in low-income settings underscores the importance of affordable, robust, and decentralized blood group testing.

Key Group Insights Across Strategic Blood Typing Markets

ASEAN countries are advancing blood safety through healthcare infrastructure investment, but adoption varies between urban tertiary centers and resource-constrained facilities. The GCC is characterized by high per-capita health spending, growing specialty care, medical tourism, and demand for automated transfusion diagnostics that support large hospital networks and centralized laboratory models.

The European Union is shaped by IVDR compliance, cross-border quality expectations, hemovigilance, and strong reference laboratory networks. BRICS countries combine high population scale with expanding diagnostic manufacturing, public health programs, and rising demand for standardized blood bank testing. G7 markets emphasize innovation, automation, data connectivity, molecular immunohematology, and patient blood management, while NATO countries increasingly view resilient blood supply chains and interoperable transfusion systems as part of healthcare readiness and emergency preparedness.

Key Country Insights in Blood Group Typing

The United States leads in advanced transfusion diagnostics, reference testing, molecular blood group genotyping, and blood bank automation, while Canada emphasizes standardized quality, donor safety, and national blood service coordination. Mexico and Brazil are expanding access to modern immunohematology testing as private hospitals and public systems upgrade blood safety capabilities and laboratory infrastructure.

The United Kingdom, Germany, France, Italy, and Spain maintain mature blood service models supported by quality systems, hemovigilance, and hospital transfusion governance, with Germany and France notable for strong diagnostic manufacturing and laboratory standards. Russia has a large hospital network with continued demand for standardized and scalable testing. China and India are high-scale opportunities driven by population size, surgery volumes, maternal health needs, trauma care, and blood safety modernization. Japan, South Korea, and Australia combine advanced healthcare systems with strong adoption of automation, molecular methods, reference laboratory expertise, and quality-assured transfusion practices.

Actionable Recommendations for Blood Group Typing Leaders

Industry leaders should prioritize platforms that combine ABO/Rh typing, antibody screening, crossmatching, extended phenotyping, and molecular genotyping within connected workflows. Differentiation will come from reducing turnaround time, minimizing manual interpretation, improving result traceability, and supporting regulation-ready documentation.

Organizations should build region-specific portfolios: high-throughput automation for mature markets, modular and cost-effective systems for emerging markets, and reference-lab solutions for complex antibody and rare donor cases. Partnerships with hospitals, blood services, and informatics vendors can accelerate adoption. Leaders should also invest in AI validation, cybersecurity, reagent supply resilience, staff training, quality control, and post-market surveillance to strengthen trust.

Research Methodology

This executive summary is grounded in secondary research from authoritative sources, including WHO blood safety data, regulatory guidance from the FDA and European Commission, transfusion medicine standards, peer-reviewed immunohematology literature, hemovigilance resources, and public information from blood services and diagnostic manufacturers.

The analysis synthesizes market drivers, technology adoption, regional healthcare capacity, regulatory frameworks, and operational needs across hospitals, donor centers, reference laboratories, and emergency care settings. Insights are presented qualitatively to avoid unsupported market-size claims and to focus on verified trends shaping the blood group typing market. Conclusion

The blood group typing market is entering a more automated, connected, and quality-focused phase. Core ABO/Rh testing remains essential, but growth is increasingly linked to extended antigen matching, molecular genotyping, AI-supported interpretation, rare donor identification, and integrated blood bank informatics.

Organizations that deliver validated accuracy, workflow efficiency, regulatory readiness, data security, and regional affordability will be best positioned. As surgical volumes, chronic disease care, trauma response, transplantation, and maternal health needs continue to drive transfusion demand, reliable blood group typing will remain central to patient safety and health system resilience.

Product Code: MRR-437D459582E9

1. Preface

1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders

2. Research Methodology

2.1. Introduction
2.2. Research Design
- 2.2.1. Primary Research
- 2.2.2. Secondary Research
2.3. Research Framework
- 2.3.1. Qualitative Analysis
- 2.3.2. Quantitative Analysis
2.4. Market Size Estimation
- 2.4.1. Top-Down Approach
- 2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations

3. Executive Summary

3.1. Introduction
3.2. CXO Perspective
3.3. Market Size & Growth Trends
3.4. Market Share Analysis, 2025
3.5. FPNV Positioning Matrix, 2025
3.6. New Revenue Opportunities
3.7. Next-Generation Business Models
3.8. Industry Roadmap

4. Market Overview

4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
- 4.2.1. Supply-Side Analysis
- 4.2.2. Demand-Side Analysis
- 4.2.3. Stakeholder Analysis
4.3. Market Dynamics
- 4.3.1. Key Drivers
- 4.3.2. Key Restraints
- 4.3.3. Key Opportunities
- 4.3.4. Key Challenges
4.4. Porter's Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
- 4.6.1. Near-Term Market Outlook (0-2 Years)
- 4.6.2. Medium-Term Market Outlook (3-5 Years)
- 4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy

5. Market Insights

5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Blood Group Typing Market, by Test Type

7.1. ABO Typing
7.2. Rh Typing
7.3. Antibody Screening
7.4. Antibody Identification
7.5. Antigen Phenotyping
7.6. Crossmatching

8. Blood Group Typing Market, by Technology

8.1. Flow Cytometry
8.2. Gel Centrifugation
8.3. Microplate Agglutination
8.4. PCR
- 8.4.1. Digital PCR
- 8.4.2. Real-Time PCR

9. Blood Group Typing Market, by Sample Type

9.1. Whole Blood
9.2. Red Cell Suspension
9.3. Serum Or Plasma
9.4. Buccal Swab

10. Blood Group Typing Market, by Automation Level

10.1. Manual Testing
10.2. Semi-Automated Testing
10.3. Fully Automated Testing

11. Blood Group Typing Market, by Application

11.1. Donor Screening
- 11.1.1. Blood Typing
- 11.1.2. Infectious Disease Screening
11.2. Newborn Screening
11.3. Pretransfusion Testing

12. Blood Group Typing Market, by End User

12.1. Blood Banks
- 12.1.1. Government Blood Banks
- 12.1.2. Private Blood Banks
12.2. Clinical Laboratories
12.3. Hospitals & Diagnostic Centers

13. Blood Group Typing Market, by Region

13.1. Asia-Pacific
13.2. North America
13.3. Latin America
13.4. Europe
13.5. Middle East
13.6. Africa

14. Blood Group Typing Market, by Group

14.1. ASEAN
14.2. GCC
14.3. European Union
14.4. BRICS
14.5. G7
14.6. NATO

15. Blood Group Typing Market, by Country

15.1. United States
15.2. Canada
15.3. Mexico
15.4. Brazil
15.5. United Kingdom
15.6. Germany
15.7. France
15.8. Russia
15.9. Italy
15.10. Spain
15.11. China
15.12. India
15.13. Japan
15.14. Australia
15.15. South Korea

16. Competitive Landscape

16.1. Market Concentration Analysis, 2025
- 16.1.1. Concentration Ratio (CR)
- 16.1.2. Herfindahl Hirschman Index (HHI)
16.2. Recent Developments & Impact Analysis, 2025
16.3. Product Portfolio Analysis, 2025
16.4. Benchmarking Analysis, 2025

17. Company Profiles

17.1. Abbott Laboratories
17.2. Agena Bioscience, Inc.
17.3. BAG Diagnostics GmbH
17.4. Beckman Coulter, Inc.
17.5. Bio-Rad Laboratories, Inc.
17.6. CareDx, Inc.
17.7. DIAGAST
17.8. DiaSorin S.p.A.
17.9. F. Hoffmann-La Roche Ltd
17.10. Fujirebio Holdings, Inc.
17.11. Grifols, S.A.
17.12. Hemo Bioscience, Inc.
17.13. Hologic, Inc.
17.14. Illumina, Inc.
17.15. Immucor, Inc.
17.16. Inno-Train Diagnostik GmbH
17.17. Lorne Laboratories
17.18. Merck KGaA
17.19. Novacyt Group
17.20. Ortho Clinical Diagnostics, Inc.
17.21. Precision BioLogic Inc.
17.22. Quotient Limited
17.23. Rapid Labs Ltd.
17.24. Siemens Healthineers AG
17.25. Sysmex Corporation
17.26. Thermo Fisher Scientific Inc.
17.27. Tulip Diagnostics (P) Ltd.